Abstract
Clinical trials using the humanized version of the anti-HER2 murine monoclonal antibody 4D5, trastuzumab, have shown antitumor activity in patients with HER2-positive metastatic breast cancer. Improved response and survival rates have been shown when trastuzumab was added to first-line combination chemotherapy with anthracycline/cyclophosphamide or paclitaxel compared with the same chemotherapy alone. Because of the promising safety and efficacy profile of trastuzumab in the metastatic setting, this novel biologic has now entered adjuvant breast cancer trials in both the United States and Europe. Five clinical trials are discussed in this report, capturing the evolving role of trastuzumab as adjuvant therapy for breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
